Legis Daily

Cosmetic Supply Chain Transparency Act of 2023

USA118th CongressHR-3622| House 
| Updated: 5/26/2023
Janice D. Schakowsky

Janice D. Schakowsky

Democratic Representative

Illinois

Cosponsors (14)
Nikema Williams (Democratic)Raúl M. Grijalva (Democratic)Sheila Jackson Lee (Democratic)Shontel M. Brown (Democratic)Debbie Dingell (Democratic)Melanie A. Stansbury (Democratic)Henry C. "Hank" Johnson (Democratic)Sheila Cherfilus-McCormick (Democratic)Doris O. Matsui (Democratic)Eleanor Holmes Norton (Democratic)Nydia M. Velázquez (Democratic)Zoe Lofgren (Democratic)Grace Meng (Democratic)Rashida Tlaib (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Cosmetic Supply Chain Transparency Act of 2023 This bill requires the Food and Drug Administration (FDA) to maintain a list of certain nonfunctional constituents in cosmetics that are harmful to human health or the environment, authorizes the FDA to request from a brand owner (i.e., the entity bringing a cosmetic to market) certain information about a cosmetic's ingredients, and addresses related issues. For each listed nonfunctional constituent, the list must identify the ingredient or cosmetic (or category of ingredient or cosmetic) in which the constituent is known or reasonably expected to be present. The FDA must also (1) establish procedures for petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance. Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request. Brand owners must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request. The bill also imposes civil penalties for brand owners and suppliers that violate this bill's provisions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 117-5539
Cosmetic Supply Chain Transparency Act of 2021
May 24, 2023
Introduced in House
May 24, 2023
Referred to the House Committee on Energy and Commerce.
May 26, 2023
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 117-5539
    Cosmetic Supply Chain Transparency Act of 2021


  • May 24, 2023
    Introduced in House


  • May 24, 2023
    Referred to the House Committee on Energy and Commerce.


  • May 26, 2023
    Referred to the Subcommittee on Health.

Health

Administrative law and regulatory proceduresAdvisory bodiesBusiness recordsCivil actions and liabilityCosmetics and personal careDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government information and archivesHazardous wastes and toxic substancesRetail and wholesale trades

Cosmetic Supply Chain Transparency Act of 2023

USA118th CongressHR-3622| House 
| Updated: 5/26/2023
Cosmetic Supply Chain Transparency Act of 2023 This bill requires the Food and Drug Administration (FDA) to maintain a list of certain nonfunctional constituents in cosmetics that are harmful to human health or the environment, authorizes the FDA to request from a brand owner (i.e., the entity bringing a cosmetic to market) certain information about a cosmetic's ingredients, and addresses related issues. For each listed nonfunctional constituent, the list must identify the ingredient or cosmetic (or category of ingredient or cosmetic) in which the constituent is known or reasonably expected to be present. The FDA must also (1) establish procedures for petitions to add substances to the list, (2) issue guidance for industry related to testing and detecting such nonfunctional constituents, and (3) establish a committee to provide advice on creating the list and developing the required industry guidance. Within a year of a nonfunctional constituent being added to the list, a supplier of an ingredient or cosmetic must test for that constituent and provide a brand owner the results and other information before selling the ingredient or cosmetic to the brand owner. A supplier of an ingredient or cosmetic must provide additional information about the item upon a brand owner's request. Brand owners must maintain records with information about the suppliers of ingredients and raw materials used in their cosmetics and provide such information to the FDA upon request. The bill also imposes civil penalties for brand owners and suppliers that violate this bill's provisions.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 117-5539
Cosmetic Supply Chain Transparency Act of 2021
May 24, 2023
Introduced in House
May 24, 2023
Referred to the House Committee on Energy and Commerce.
May 26, 2023
Referred to the Subcommittee on Health.
  • Bill from Previous Congress

    HR 117-5539
    Cosmetic Supply Chain Transparency Act of 2021


  • May 24, 2023
    Introduced in House


  • May 24, 2023
    Referred to the House Committee on Energy and Commerce.


  • May 26, 2023
    Referred to the Subcommittee on Health.
Janice D. Schakowsky

Janice D. Schakowsky

Democratic Representative

Illinois

Cosponsors (14)
Nikema Williams (Democratic)Raúl M. Grijalva (Democratic)Sheila Jackson Lee (Democratic)Shontel M. Brown (Democratic)Debbie Dingell (Democratic)Melanie A. Stansbury (Democratic)Henry C. "Hank" Johnson (Democratic)Sheila Cherfilus-McCormick (Democratic)Doris O. Matsui (Democratic)Eleanor Holmes Norton (Democratic)Nydia M. Velázquez (Democratic)Zoe Lofgren (Democratic)Grace Meng (Democratic)Rashida Tlaib (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresAdvisory bodiesBusiness recordsCivil actions and liabilityCosmetics and personal careDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Government information and archivesHazardous wastes and toxic substancesRetail and wholesale trades